UK and India sign agreement to help ensure drug quality

By Dan Stanton

- Last updated on GMT

MHRA and CDSCO sign memorandom of understanding
MHRA and CDSCO sign memorandom of understanding

Related tags Contract

The MHRA has signed a Memorandum of Understanding (MOU) with Indian regulators to help ensure the quality of drugs in the UK.

The agreement, signed today, is the first between India’s Central Drugs Standard Control Organisation (CDSCO) and the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) and intends to increase collaboration and strengthen ties between the two countries by promoting each other’s regulatory framework, requirements and processes

But the MoU will also help to ensure the safety of drug products imported from India into the UK, according to MHRA Chairman Sir Michael Rawlins.

“It’s essential that the commitment to good quality manufacturing comes right down from the top levels of management to those on the factory floor, and throughout the entire industry,” ​he said in a statement.

“Indian firms already accept and understand this, and the MOU is part of a concerted effort to ensure the UK and wider global public continue to have access to quality and safe medicines.”

A spokesman told this publication "the MoU won’t have a direct impact on the day to day running of the MHRA.  Rather it serves as a statement to cement our already existing working relationship with India and to provide a platform from which to further develop that partnership."

Quality Concerns

There have been a number of concerns surrounding the quality of Indian-made drugs and drug products.

A number of facilities have been hit with warning letters and import alerts due to cGMP violations, Wockhardt​ and Ranbaxy​ being two of the most high-profile over the past few years. But smaller API makers​ and contract services firms such as GVK BioSciences​ have also been accused of data integrity issues.

According to the India Brand Equity Foundation (IBEF), India supplies around 25% of all UK medicines.

Despite this, just 49 of the 675 inspections (about 7%) carried out by the UK agency in 2014 were in India. The MHRA told in-Pharmatechnologist the MoU would not directly impact the number of inspections undertaken.

Related news

Show more

Related products

show more

Increasing the Bioavailability of Oncology Drugs

Increasing the Bioavailability of Oncology Drugs

Content provided by Lonza Small Molecules | 13-Nov-2023 | White Paper

Oral tyrosine kinase inhibitors (TKIs) are a class of cancer drugs that can be highly susceptible to issues with solubility in the gastrointestinal tract

Efficient Freezing & Storage of Biopharmaceuticals

Efficient Freezing & Storage of Biopharmaceuticals

Content provided by Single Use Support | 06-Nov-2023 | White Paper

Various options exist for freezing biopharmaceutical bulk material, but selecting the most effective and efficient approach for each cold chain can be...

Manufacturing Drugs with Highly Potent APIs

Manufacturing Drugs with Highly Potent APIs

Content provided by Altasciences | 28-Sep-2023 | White Paper

In this issue of The Altascientist, we examine the critical considerations for the safe and compliant manufacture of drugs with highly potent APIs (HPAPIs),...

Follow us